TYME - Tyme Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3800
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close1.3800
Open1.3900
Bid1.3600 x 800
Ask1.3800 x 1300
Day's Range1.3000 - 1.4100
52 Week Range1.3000 - 4.6420
Volume250,459
Avg. Volume361,457
Market Cap154.485M
Beta (3Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)-0.2710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
  • GlobeNewswire17 hours ago

    Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the company will host a conference call and live webcast on Wednesday, May 29, 2019, at 8:30 A.M. ET to report its fourth quarter and fiscal year 2019 financial and operating results. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties.

  • GlobeNewswire2 days ago

    TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced the initiation of the HopES trial conducted in partnership with The Joseph Ahmed Foundation to better understand and help manage high-risk sarcomas which are ultra-rare cancers with high unmet medical need. "There is an urgent need for more effective treatment options for patients with high-risk sarcomas, including Ewing’s sarcoma,” said Sant Chawla, M.D., Director of the Sarcoma Oncology Research Center, Santa Monica, CA and lead investigator for the HopES trial. "I was encouraged by the initial clinical trial data for SM-88 in metastatic sarcomas.  This study has the potential to provide a new treatment option for patients with Ewing’s sarcoma who do not reach complete remission with first line treatment and patients with other sarcomas after progression.

  • GlobeNewswire5 days ago

    TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers

    Tyme Technologies, Inc.  (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that it has received notification that the United States Patent and Trademark Office (USPTO) intends to issue another patent related to TYME’s technology platform. U.S. Patent No.10,307,465 will be directed to methods for treating cancer using tyrosine hydroxylase inhibitors, such as TYME’s lead compound SM-88 (racemetyrosine), to make cancer cells more accessible to oxidative stress.

  • GlobeNewswire16 days ago

    Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will participate at the Oppenheimer Oncology Insight Summit in New York on Thursday, May 16, 2019. In one-on-one settings, the company will present its corporate overview for 2019 with special focus on advances in the science of cancer metabolism and clinical developments in lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers. The presentation will be accessible on the events page under the Investor Relations section of Tyme Technologies’ website at www.tymeinc.com.

  • GlobeNewswire23 days ago

    Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2019 at the BioNJ 9th Annual BioPartnering Conference on Wednesday, May 8, 2019. Co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, the conference brings together biopharmaceutical companies, investors, and academic collaborators across the Northeast to Mid-Atlantic states. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer metabolism-based therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

  • GlobeNewswire24 days ago

    Tyme Technologies to Participate at the SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on May 7th

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the SunTrust Robinson Humphrey’s 5th Annual Life sciences Summit in New York on May 7th. In one-on-one settings, the company will present its corporate overview for 2019 with special focus on advances in science and clinical developments in oncology and orphan diseases.

  • GlobeNewswirelast month

    TYME Announces USAN Approval of Generic Name “Racemetyrosine” for SM-88

    Tyme Technologies, Inc.  (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that the United States Adopted Name (USAN) Council recently granted “racemetyrosine” as the generic name for SM-88, TYME’s lead pipeline candidate. The purpose of the United States Adopted Names Council is to serve the health professions in the United States by selecting simple, informative, and unique generic names for therapies by establishing logical nomenclature classifications based on pharmacological and/or chemical relationships.

  • GlobeNewswire2 months ago

    TYME’s SM-88 First Human Study in Patients with Metastatic Cancer Published in the Journal, Investigational New Drugs

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the results of its first human study, completed as of September 15, 2017 and designed to evaluate the safety, tolerability and efficacy of SM-88 in patients with advanced metastatic cancers, was published online on March 30th 2019 in the peer-reviewed journal Investigational New Drugs.

  • GlobeNewswire2 months ago

    TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced the closing of its underwritten registered offering with a group of three existing and one new investors resulting in gross proceeds of $12 million. TYME is in the process of finalizing a randomized pivotal trial protocol amendment for use of SM-88 in third-line pancreatic cancer.

  • GlobeNewswire2 months ago

    TYME Announces Dismissal of Class Action Lawsuit

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM) announced the consolidated class action complaint filed in the United States District Court for the Southern District of New York (Case No. 1:19-cv-00843) was voluntarily dismissed, without prejudice against all the defendants, by the plaintiff and his counsel on March 28, 2019. TYME had previously stated the class action allegations were meritless and is pleased that plaintiff and his counsel agreed to voluntarily withdraw the case. The case was never formally certified as a class action lawsuit.

  • GlobeNewswire2 months ago

    Tyme Technologies Announces Pricing of its $12 Million Registered Offering

    Tyme Technologies, Inc. (TYME) announced today that it has priced a registered offering of 8 million shares of its common stock, par value $0.0001 per share, and warrants to purchase 8 million shares of its common stock at a combined purchase price of $1.50 per share of common stock and accompanying warrant, resulting in gross proceeds of approximately $12 million. The warrants will be exercisable beginning six months after issuance at a price of $2.00 per share of common stock and have a term of five years commencing on the date of issuance. The shares of common stock and the warrants will be immediately separable and will be issued separately.

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT: VALE TYME UXIN UMC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, March 28, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.

  • ACCESSWIRE2 months ago

    DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / March 28, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tyme Technologies, Inc. ("Tyme" or "the Company") (NASDAQ: TYME) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between June 22, 2018 and November 19, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before March 29, 2019.

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline – TYME  

    NEW YORK, March 28, 2019 -- Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ: TYME) and.

  • ACCESSWIRE2 months ago

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of TYME, GE and AVP

    CEDARHURST, NY / ACCESSWIRE / March 28, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • ACCESSWIRE2 months ago

    2-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / March 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tyme Technologies, Inc. ("Tyme" or "the Company") (NASDAQ: TYME) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

  • ACCESSWIRE2 months ago

    CLASS ACTION UPDATE for ZIV, TYME and UMC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / March 27, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...

  • ACCESSWIRE2 months ago

    Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action

    NEW YORK, NY / ACCESSWIRE / March 27, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review ...

  • GlobeNewswire2 months ago

    Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX)

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.

  • GlobeNewswire2 months ago

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VALE, TYME, MHLD and BPI

    The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • ACCESSWIRE2 months ago

    LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tyme Technologies, Inc. To Contact The Firm

    NEW YORK, NY / ACCESSWIRE / March 26, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tyme Technologies, Inc. ("Tyme" or the "Company") (TYME) of the March 29, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Tyme stock or optionsbetween March 14, 2018 and January 18, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/Tyme. You can also contact us by calling Richard Gonnello toll free at877-247-4292 or at 212-983-9330 or by sending an e-mail torgonnello@faruqilaw.com.

  • ACCESSWIRE2 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline - TYME

    NEW YORK, NY / ACCESSWIRE / March 26, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. ("Tyme" or the "Company") (TYME) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 19-cv-00843, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Tyme securities between March 14, 2018 and January 18, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • GlobeNewswire2 months ago

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TYME, TAP, KHC and SYNH

    NEW YORK, March 26, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.

  • GlobeNewswire2 months ago

    TYME MARCH 29 DEADLINE: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Tyme Technologies, Inc. – TYME

    Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Tyme Technologies, Inc. (TYME) from March 14, 2018 through January 18, 2019, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than March 29, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

  • ACCESSWIRE2 months ago

    SHAREHOLDER ALERT: ARLO TYME AVP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / March 22, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you ...